{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:53:16Z","timestamp":1793253196372,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Ment Health Syst"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug markets are dynamic systems which change based on demand, competition, legislation and revenue. Shifts that are not met with immediate and appropriate responses from the healthcare system can lead to public health crises with tragic levels of morbidity and mortality, as experienced Europe in the early 1990s and as is the case in North America currently. The major feature of the current drug market shift in North America is towards highly potent synthetic opioids such as fentanyl and fentanyl analogues. An additional spike in stimulant use further complicates this issue. Without understanding the ever-changing dynamics of drug markets and consequent patterns of drug use, the healthcare system will continue to be ineffective in its response, and morbidity and mortality will continue to increase. Economic perspectives are largely neglected in research and clinical contexts, but better treatment alternatives need to consider the large-scale macroeconomic conditions of drug markets as well as the behavioural economics of individual substance use. It is important for policy makers, health authorities, first responders and medical providers to be aware of the clinical implications of  drug market\u00a0changes in order to best serve people who use drugs. Only with significant clinical research, a comprehensive reorganization of the system of care across all sectors, and an evidence-driven governance, will we be successful in addressing the challenges brought on by the recent shifts in drug markets.<\/jats:p>","DOI":"10.1186\/s13033-021-00512-9","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T11:12:19Z","timestamp":1639998739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Shifting North American drug markets and challenges for the system of care"],"prefix":"10.1186","volume":"15","author":[{"given":"R. Michael","family":"Krausz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-8402","authenticated-orcid":false,"given":"Jean N.","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickie","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Budd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S. H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian W. L.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Seethapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"512_CR1","unstructured":"BC Coroners Service. Illicit drug toxicity deaths in BC: January 1st, 2011\u2013July 31st, 2021. 2021;21. https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicit-drug.pdf. Accessed 23 Nov 2021."},{"key":"512_CR2","unstructured":"BC Centre for Disease Control. BC COVID-19 data. Provincial Health Services Authority. 2020. http:\/\/www.bccdc.ca\/health-info\/diseases-conditions\/covid-19\/data.  Accessed 23 Nov 2021."},{"key":"512_CR3","volume-title":"Overdose prevention services indicators. Overdose response indicators","author":"BC Centre for Disease Control","year":"2021","unstructured":"BC Centre for Disease Control. Overdose prevention services indicators. Overdose response indicators. Vancouver: BCCDC; 2021."},{"issue":"5","key":"512_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1176\/appi.ps.202000534","volume":"72","author":"J Baillargeon","year":"2021","unstructured":"Baillargeon J, Polychronopoulou E, Kuo Y-F, Raji MA. The impact of substance use disorder on COVID-19 outcomes. Psychiatr Serv. 2021;72(5):578\u201381.","journal-title":"Psychiatr Serv"},{"key":"512_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.puhe.2020.05.010","volume":"183","author":"R Armitage","year":"2020","unstructured":"Armitage R, Nellums LB. Substance misuse during COVID-19: protecting people who use drugs. Public Health. 2020;183:63.","journal-title":"Public Health"},{"key":"512_CR6","unstructured":"Canadian Centre on Substance Use and Addiction. Impacts of the COVID-19 pandemic on people who use substances: what we heard. 2020. https:\/\/www.ccsa.ca\/sites\/default\/files\/2020-07\/CCSA-COVID-19-Impacts-on-People-Who-Use-Substances-Report-2020-en.pdf. Accessed 23 Nov 2021."},{"key":"512_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.01.010","author":"D Ciccarone","year":"2019","unstructured":"Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019. https:\/\/doi.org\/10.1016\/j.drugpo.2019.01.010.","journal-title":"Int J Drug Policy"},{"key":"512_CR8","unstructured":"International Narcotics Control Board. Narcotic Drugs Technical Report 2019. New York, NY. 2020. https:\/\/www.incb.org\/incb\/en\/narcotic-drugs\/Technical_Reports\/2019\/narcotic-drugs-technical-report-2019.html. Accessed 23 Nov 2021."},{"issue":"6","key":"512_CR9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamainternmed.2015.0914","volume":"175","author":"MR Larochelle","year":"2015","unstructured":"Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med. 2015;175(6):978\u201387.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"512_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpain.2005.05.004","volume":"6","author":"TJ Cicero","year":"2005","unstructured":"Cicero TJ, Inciardi JA, Mu\u00f1oz A. Trends in abuse of OxyContin\u00ae and other opioid analgesics in the United States: 2002\u20132004. J Pain. 2005;6(10):662\u201372.","journal-title":"J Pain"},{"issue":"5","key":"512_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/10408444.2020.1762539","volume":"50","author":"VL Alves","year":"2020","unstructured":"Alves VL, Gon\u00e7alves JL, Aguiar J, Teixeira HM, C\u00e2mara JS. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. Crit Rev Toxicol. 2020;50(5):359\u201382.","journal-title":"Crit Rev Toxicol"},{"key":"512_CR12","doi-asserted-by":"publisher","first-page":"110742","DOI":"10.1016\/j.forsciint.2021.110742","volume":"321","author":"SPB Ovenden","year":"2021","unstructured":"Ovenden SPB, McDowall LJ, McKeown HE, McGill NW, Jones OAH, Pearson JR, et al. Investigating the chemical impurity profiles of fentanyl preparations and precursors to identify chemical attribution signatures for synthetic method attribution. Forensic Sci Int. 2021;321:110742.","journal-title":"Forensic Sci Int"},{"key":"512_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000717","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021. https:\/\/doi.org\/10.1097\/YCO.0000000000000717.","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"512_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1556-4029.2007.00597.x","volume":"53","author":"KL Woodall","year":"2008","unstructured":"Woodall KL, Martin TL, McLellan BA. Oral abuse of fentanyl patches (Duragesic\u00ae): seven case reports. J Forensic Sci. 2008;53(1):222\u20135.","journal-title":"J Forensic Sci"},{"issue":"6","key":"512_CR15","doi-asserted-by":"publisher","first-page":"JFS2004143","DOI":"10.1520\/JFS04143","volume":"49","author":"PK Lilleng","year":"2004","unstructured":"Lilleng PK, Mehlum LI, Bachs L, Morild I. Deaths after intravenous misuse of transdermal fentanyl. J Forensic Sci. 2004;49(6):JFS2004143-3.","journal-title":"J Forensic Sci"},{"key":"512_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000712","author":"RM Krausz","year":"2021","unstructured":"Krausz RM, Westenberg JN, Ziafat K. The opioid overdose crisis as a global health challenge. Curr Opin Psychiatry. 2021. https:\/\/doi.org\/10.1097\/YCO.0000000000000712.","journal-title":"Curr Opin Psychiatry"},{"key":"512_CR17","doi-asserted-by":"publisher","first-page":"102616","DOI":"10.1016\/j.drugpo.2019.102616","volume":"76","author":"H Alho","year":"2020","unstructured":"Alho H, Dematteis M, Lembo D, Maremmani I, Roncero C, Somaini L. Opioid-related deaths in Europe: strategies for a comprehensive approach to address a major public health concern. Int J Drug Policy. 2020;76:102616.","journal-title":"Int J Drug Policy"},{"key":"512_CR18","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European Drug Report. European Union Publications Office. 2019. http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/4541\/TDAT17001ENN.pdf_en. Accessed 23 Nov 2021."},{"issue":"2","key":"512_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1556-4029.2008.00669.x","volume":"53","author":"JS Denton","year":"2008","unstructured":"Denton JS, Donoghue ER, McReynolds J, Kalelkar MB. An epidemic of illicit fentanyl deaths in Cook County, Illinois: September 2005 through April 2007. J Forensic Sci. 2008;53(2):452\u20134.","journal-title":"J Forensic Sci"},{"key":"512_CR20","volume-title":"Fentanyl: China\u2019s deadly export to the United States","author":"S O\u2019Connor","year":"2017","unstructured":"O\u2019Connor S. Fentanyl: China\u2019s deadly export to the United States. Washington: US\u2013China Economic and Security Review Commission; 2017."},{"issue":"2","key":"512_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bph.14860","volume":"177","author":"R Hill","year":"2020","unstructured":"Hill R, Santhakumar R, Dewey W, Kelly E, Henderson G. Fentanyl depression of respiration: comparison with heroin and morphine. Br J Pharmacol. 2020;177(2):254\u201365.","journal-title":"Br J Pharmacol"},{"key":"512_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.drugpo.2017.05.023","volume":"46","author":"JJ Carroll","year":"2017","unstructured":"Carroll JJ, Marshall BDL, Rich JD, Green TC. Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: a mixed methods study. Int J Drug Policy. 2017;46:136\u201345.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"512_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/02791072.2017.1394508","volume":"50","author":"SG Mars","year":"2018","unstructured":"Mars SG, Ondocsin J, Ciccarone D. Sold as heroin: perceptions and use of an evolving drug in Baltimore, MD. J Psychoact Drugs. 2018;50(2):167\u201376.","journal-title":"J Psychoact Drugs"},{"key":"512_CR24","first-page":"9","volume":"63","author":"N Mathew","year":"2021","unstructured":"Mathew N, Wong JSH, Krausz RM. An inside look at Bc\u2019s illicit drug market during the COVID-19 pandemic. BC Med J. 2021;63:9\u201313.","journal-title":"BC Med J"},{"issue":"1","key":"512_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1742-7843.2006.pto_233.x","volume":"98","author":"EJ Rook","year":"2006","unstructured":"Rook EJ, Van Ree JM, Van Den Brink W, Hillebrand MJX, Huitema ADR, Hendriks VM, et al. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol. 2006;98(1):86\u201396.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"512_CR26","unstructured":"BC Coroners Service. Knowledge update: mode of consumption. 2020. https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/statistical\/illicit-drug.pdf. Accessed 23 Nov 2021."},{"key":"512_CR27","volume-title":"Adulterants, contaminants and co-occurring substances in drugs on the illegal market in Canada","author":"DE Payer","year":"2020","unstructured":"Payer DE, Young MM, Maloney-Hall B, Mill C, Leclerc P, Buxton J, et al. Adulterants, contaminants and co-occurring substances in drugs on the illegal market in Canada. Ottawa: Canadian Centre on Substance Use and Addiction; 2020."},{"key":"512_CR28","first-page":"2001","volume-title":"National drug threat assessment","author":"Drug Enforcement Administration","year":"2019","unstructured":"Drug Enforcement Administration. National drug threat assessment. Arlington: Drug Enforcement Administration Strategic Intelligence Section, US Department of Justice; 2019. p. 2001\u201320."},{"issue":"11","key":"512_CR29","doi-asserted-by":"publisher","first-page":"e1914666","DOI":"10.1001\/jamanetworkopen.2019.14666","volume":"2","author":"JE Zibbell","year":"2019","unstructured":"Zibbell JE, Aldridge AP, Cauchon D, DeFiore-Hyrmer J, Conway KP. Association of law enforcement seizures of heroin, fentanyl, and carfentanil with opioid overdose deaths in Ohio, 2014\u20132017. JAMA Netw Open. 2019;2(11):e1914666\u2013e1914666. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.14666.","journal-title":"JAMA Netw Open"},{"key":"512_CR30","volume-title":"Illicit fentanyl and China\u2019s role","author":"Congressional Research Service","year":"2021","unstructured":"Congressional Research Service. Illicit fentanyl and China\u2019s role. Washington: Congressional Research Service; 2021."},{"key":"512_CR31","unstructured":"Canadian Integrated Response to Organized Crime. Closing in on meth: The Canadian Enforcement Strategy (2020\u20132021). 2020. https:\/\/www.multibriefs.com\/briefs\/cacp\/National%20Methamphetamine%20Strategy%20-%20English%20(Jan2020)%20(004).pdf. Accessed 23 Nov 2021."},{"key":"512_CR32","unstructured":"Royal Canadian Mountain Police. Massive drug lab bust highlights coordinated approach to gangs and organized crime. Newsroom. Surrey, BC. 2021. https:\/\/bc-cb.rcmp-grc.gc.ca\/ViewPage.action?siteNodeId=2126&languageId=1&contentId=69480. Accessed 2 Jun 2021."},{"key":"512_CR33","unstructured":"Canada Border Services Agency. Canada Border Services Agency seizures. Securing the border. 2021. https:\/\/www.cbsa-asfc.gc.ca\/security-securite\/seizure-saisie-eng.html. Accessed 30 Jun 2021."},{"key":"512_CR34","unstructured":"Centers for Disease Control and Prevention. 2019 drug overdose death rates. 2021. https:\/\/www.cdc.gov\/drugoverdose\/data\/statedeaths\/drug-overdose-death-2019.html. Accessed 9 Jun 2021."},{"key":"512_CR35","volume-title":"Apparent opioid and stimulant toxicity deaths","author":"Opioid Overdose Surveillance Task Group of the Special Advisory Committee on the Epidemic of Opioid Overdoses","year":"2021","unstructured":"Opioid Overdose Surveillance Task Group of the Special Advisory Committee on the Epidemic of Opioid Overdoses. Apparent opioid and stimulant toxicity deaths. Ottawa: PHAC; 2021."},{"key":"512_CR36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.drugalcdep.2017.08.021","volume":"180","author":"I Sinicina","year":"2017","unstructured":"Sinicina I, Sachs H, Keil W. Post-mortem review of fentanyl-related overdose deaths among identified drug users in Southern Bavaria, Germany, 2005\u20132014. Drug Alcohol Depend. 2017;180:286\u201391.","journal-title":"Drug Alcohol Depend"},{"key":"512_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13092","author":"S Martinez","year":"2020","unstructured":"Martinez S, Jones JD, Brandt L, Campbell ANC, Abbott R, Comer SD. The increasing prevalence of fentanyl: a urinalysis-based study among individuals with opioid use disorder in New York City. Am J Addict. 2020. https:\/\/doi.org\/10.1111\/ajad.13092.","journal-title":"Am J Addict"},{"issue":"107547","key":"512_CR38","first-page":"1","volume":"204","author":"KB Morales","year":"2019","unstructured":"Morales KB, Park JN, Glick JL, Rouhani S, Green TC, Sherman SG. Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities. Drug Alcohol Depend. 2019;204(107547):1\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"512_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11419-017-0379-4","volume":"36","author":"N Misailidi","year":"2018","unstructured":"Misailidi N, Papoutsis I, Nikolaou P, Dona A, Spiliopoulou C, Athanaselis S. Fentanyls continue to replace heroin in the drug arena: the cases of ocfentanil and carfentanil. Forensic Toxicol. 2018;36(1):12\u201332. https:\/\/doi.org\/10.1007\/s11419-017-0379-4.","journal-title":"Forensic Toxicol"},{"issue":"4","key":"512_CR40","first-page":"177","volume":"63","author":"R Purssell","year":"2021","unstructured":"Purssell R, Buxton JA, Godwin J, Moe J. Potent sedatives in opioids in BC: implications for resuscitation, and benzodiazepine and etizolam withdrawal. BC Med J. 2021;63(4):177\u20138.","journal-title":"BC Med J"},{"issue":"9","key":"512_CR41","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1038\/sj.npp.1301602","volume":"33","author":"M Lenoir","year":"2008","unstructured":"Lenoir M, Ahmed SH. Supply of a nondrug substitute reduces escalated heroin consumption. Neuropsychopharmacology. 2008;33(9):2272\u201382.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"512_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.drugalcdep.2006.03.007","volume":"85","author":"MK Greenwald","year":"2006","unstructured":"Greenwald MK, Hursh SR. Behavioral economic analysis of opioid consumption in heroin-dependent individuals: effects of unit price and pre-session drug supply. Drug Alcohol Depend. 2006;85(1):35\u201348.","journal-title":"Drug Alcohol Depend"},{"key":"512_CR43","unstructured":"BC Emergency Health Services. Overdose response in BC Communities. 2021. http:\/\/www.bcehs.ca\/health-info-site\/Documents\/OverdoseResponseinBCCommunitiesPDF.pdf. Accessed 23 Nov 2021."},{"key":"512_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","volume":"74","author":"SM Silverstein","year":"2019","unstructured":"Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. \u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76\u201383.","journal-title":"Int J Drug Policy"},{"key":"512_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jsat.2020.01.010","volume":"112","author":"E Merchant","year":"2020","unstructured":"Merchant E, Burke D, Shaw L, Tookes H, Patil D, Barocas JA, et al. Hospitalization outcomes of people who use drugs: one size does not fit all. J Subst Abuse Treat. 2020;112:23\u20138.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"512_CR46","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s11414-020-09710-8","volume":"47","author":"G Neimark","year":"2020","unstructured":"Neimark G, Tjoa C. Treating fentanyl withdrawal. J Behav Health Serv Res. 2020;47(4):614\u20135.","journal-title":"J Behav Health Serv Res"},{"key":"512_CR47","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/add.15376","volume":"116","author":"ASB Bohnert","year":"2021","unstructured":"Bohnert ASB, Lin LA. It is time to recognize that synthetic opioids are not going away. Addiction. 2021;116:1313\u20138.","journal-title":"Addiction"},{"issue":"2","key":"512_CR48","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1017\/cem.2019.471","volume":"22","author":"J Moe","year":"2020","unstructured":"Moe J, Godwin J, Purssell R, O\u2019Sullivan F, Hau JP, Purssell E, et al. Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review. Can J Emerg Med. 2020;22(2):178\u201386.","journal-title":"Can J Emerg Med"},{"issue":"1","key":"512_CR49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ajad.13069","volume":"30","author":"D Antoine","year":"2021","unstructured":"Antoine D, Huhn AS, Strain EC, Turner G, Jardot J, Hammond AS, et al. Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine\/naloxone. Am J Addict. 2021;30(1):83\u20137.","journal-title":"Am J Addict"},{"key":"512_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003410.pub3","author":"M Ferri","year":"2010","unstructured":"Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev. 2010. https:\/\/doi.org\/10.1002\/14651858.CD003410.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"512_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-016-0127-9","volume":"14","author":"S Boyd","year":"2017","unstructured":"Boyd S, Murray D, MacPherson D. Telling our stories: heroin-assisted treatment and SNAP activism in the Downtown Eastside of Vancouver. Harm Reduct J. 2017;14(1):1\u201314.","journal-title":"Harm Reduct J"},{"key":"512_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000499","author":"JL Moreno","year":"2019","unstructured":"Moreno JL, Wakeman SE, Duprey MS, Roberts RJ, Jacobson JS, Devlin JW. Predictors for 30-Day and 90-day hospital readmission among patients with opioid use disorder. J Addict Med. 2019. https:\/\/doi.org\/10.1097\/ADM.0000000000000499.","journal-title":"J Addict Med"},{"issue":"12","key":"512_CR53","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.2105\/AJPH.2015.302885","volume":"105","author":"L Ti","year":"2015","unstructured":"Ti L, Ti L. Leaving the hospital against medical advice among people who use illicit drugs: a systematic review. Am J Public Health. 2015;105(12):e53\u20139.","journal-title":"Am J Public Health"},{"key":"512_CR54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","volume":"193","author":"MS Ellis","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14\u201320.","journal-title":"Drug Alcohol Depend"},{"issue":"S1","key":"512_CR55","doi-asserted-by":"publisher","first-page":"S","DOI":"10.1089\/pop.2020.0230","volume":"24","author":"JK Niles","year":"2021","unstructured":"Niles JK, Gudin J, Radcliff J, Kaufman HW. The opioid epidemic within the COVID-19 pandemic: drug testing in 2020. Popul Health Manag. 2021;24(S1):S-43.","journal-title":"Popul Health Manag."},{"issue":"6","key":"512_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0234809","volume":"15","author":"C Ronsley","year":"2020","unstructured":"Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, et al. Treatment of stimulant use disorder: a systematic review of reviews. PLoS ONE. 2020;15(6):1\u201322. https:\/\/doi.org\/10.1371\/journal.pone.0234809.","journal-title":"PLoS ONE"},{"key":"512_CR57","doi-asserted-by":"crossref","unstructured":"Hedegaard H, Mini\u00f1o AM, Warner M. Drug overdose deaths in the United States, 1999\u20132019. NCHS data brief. Hyattsville, MD. 2020. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db394-H.pdf. Accessed 23 Nov 2021.","DOI":"10.15620\/cdc:112340"},{"key":"512_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/0706743721993634","author":"RM Krausz","year":"2021","unstructured":"Krausz RM, Wong JSH, Westenberg JN, Choi F, Sch\u00fctz CG, Jang KL. Canada\u2019s response to the dual public health crises: a cautionary tale. Can J Psychiatry. 2021. https:\/\/doi.org\/10.1177\/0706743721993634.","journal-title":"Can J Psychiatry"},{"key":"512_CR59","volume-title":"Risk mitigation: in the context of dual public health emergencies","author":"British Columbia Centre on Substance Use","year":"2020","unstructured":"British Columbia Centre on Substance Use. Risk mitigation: in the context of dual public health emergencies. Vancouver: British Columbia Centre on Substance Use; 2020."},{"key":"512_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(21)00393-x","author":"RM Krausz","year":"2021","unstructured":"Krausz RM, Westenberg JN, Vogel M. Addressing fentanyl use disorder with fentanyl-assisted treatment? Lancet Psychiatry. 2021. https:\/\/doi.org\/10.1016\/s2215-0366(21)00393-x.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"512_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-020-00412-0","volume":"17","author":"M Liebrenz","year":"2020","unstructured":"Liebrenz M, Gamma A, Buadze A, Schleifer R, Baggio S, Schwartz B, et al. Fifteen years of heroin-assisted treatment in a Swiss prison\u2014a retrospective cohort study. Harm Reduct J. 2020;17(1):1\u20138.","journal-title":"Harm Reduct J"},{"issue":"6","key":"512_CR62","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s11524-008-9312-9","volume":"85","author":"E Oviedo-Joekes","year":"2008","unstructured":"Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh DC, et al. The North American Opiate Medication Initiative (NAOMI): profile of participants in North America\u2019s first trial of heroin-assisted treatment. J Urban Heal. 2008;85(6):812\u201325.","journal-title":"J Urban Heal"}],"container-title":["International Journal of Mental Health Systems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13033-021-00512-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13033-021-00512-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13033-021-00512-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T11:25:42Z","timestamp":1639999542000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmhs.biomedcentral.com\/articles\/10.1186\/s13033-021-00512-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["512"],"URL":"https:\/\/doi.org\/10.1186\/s13033-021-00512-9","relation":{},"ISSN":["1752-4458"],"issn-type":[{"value":"1752-4458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"12 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MV declares research grant from Novartis, and consulting fees from Camurus. All other authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}